Establishment Labs (NASDAQ:ESTA) Receives New Coverage from Analysts at Stephens

Analysts at Stephens started coverage on shares of Establishment Labs (NASDAQ:ESTA) in a research report issued to clients and investors on Thursday, June 6th, Marketbeat Ratings reports. The firm set an “overweight” rating and a $37.00 price target on the stock. Stephens’ target price points to a potential upside of 72.25% from the stock’s current price.

A number of other research firms also recently weighed in on ESTA. BTIG Research reissued a “buy” rating and issued a $40.00 price target on shares of Establishment Labs in a research note on Monday, March 25th. ValuEngine cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research report on Monday, June 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Establishment Labs currently has a consensus rating of “Buy” and an average target price of $35.20.

Shares of ESTA stock traded down $0.51 during trading hours on Thursday, hitting $21.48. The company had a trading volume of 73,900 shares, compared to its average volume of 59,944. Establishment Labs has a 12 month low of $20.05 and a 12 month high of $30.70. The company has a market cap of $448.80 million and a price-to-earnings ratio of -19.18. The stock’s fifty day moving average is $23.60. The company has a debt-to-equity ratio of 0.38, a current ratio of 5.54 and a quick ratio of 4.10.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.13). The business had revenue of $20.78 million during the quarter, compared to analyst estimates of $18.50 million. Establishment Labs had a negative return on equity of 68.22% and a negative net margin of 37.74%. On average, research analysts expect that Establishment Labs will post -1.93 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Establishment Labs by 159.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 102,900 shares of the company’s stock valued at $2,822,000 after acquiring an additional 63,300 shares in the last quarter. RTW Investments LP grew its holdings in shares of Establishment Labs by 9.3% in the 4th quarter. RTW Investments LP now owns 848,058 shares of the company’s stock valued at $22,740,000 after acquiring an additional 72,249 shares in the last quarter. Pura Vida Investments LLC lifted its stake in Establishment Labs by 38.3% in the 4th quarter. Pura Vida Investments LLC now owns 287,399 shares of the company’s stock valued at $7,880,000 after purchasing an additional 79,517 shares during the last quarter. BlackRock Inc. acquired a new stake in Establishment Labs in the 3rd quarter valued at about $5,088,000. Finally, Nantahala Capital Management LLC lifted its stake in Establishment Labs by 148.0% in the 4th quarter. Nantahala Capital Management LLC now owns 495,958 shares of the company’s stock valued at $13,599,000 after purchasing an additional 295,958 shares during the last quarter. Hedge funds and other institutional investors own 25.77% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic plastic surgery and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products that is used to remove blood, lipids, and other components from adipose tissue.

Read More: Trading on Margin

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.